Y-mabs Therapeutics Inc. (YMAB)

$14.39

-0.06

(-0.42%)▲

Live

Performance

  • $13.79
    $14.41
    $14.39
    downward going graph

    4.17%

    Downside

    Day's Volatility :4.3%

    Upside

    0.14%

    downward going graph
  • $4.69
    $20.90
    $14.39
    downward going graph

    67.41%

    Downside

    52 Weeks Volatility :77.56%

    Upside

    31.15%

    downward going graph

Returns

PeriodY-mabs Therapeutics Inc.Sector (Health Care)Index (Russel 2000)
3 Months
18.83%
3.6%
0.0%
6 Months
-4.68%
10.2%
0.0%
1 Year
174.71%
19.6%
0.0%
3 Years
-44.99%
16.8%
-23.0%

Highlights

Market Capitalization
632.9M
Book Value
$2.14
Earnings Per Share (EPS)
-0.56
Wall Street Target Price
20.8
Profit Margin
-28.44%
Operating Margin TTM
-42.94%
Return On Assets TTM
-12.5%
Return On Equity TTM
-24.61%
Revenue TTM
86.5M
Revenue Per Share TTM
1.98
Quarterly Revenue Growth YOY
9.9%
Gross Profit TTM
57.7M
EBITDA
-27.0M
Diluted Eps TTM
-0.56
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.63
EPS Estimate Next Year
-0.53
EPS Estimate Current Quarter
-0.13
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    76%Buy
    15%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Y-mabs Therapeutics Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 44.54%

Current $14.39
Target $20.80

Technicals Summary

Sell

Neutral

Buy

Y-mabs Therapeutics Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Y-mabs Therapeutics Inc.
Y-mabs Therapeutics Inc.
10.64%
-4.68%
174.71%
-44.99%
-48.72%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Y-mabs Therapeutics Inc.
Y-mabs Therapeutics Inc.
NA
NA
NA
-0.63
-0.25
-0.12
NA
2.14
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Y-mabs Therapeutics Inc.
Y-mabs Therapeutics Inc.
Buy
$632.9M
-48.72%
NA
-28.44%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Y-mabs Therapeutics Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 19.93M → 22.79M (in $), with an average increase of 12.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -988.0K → -9.24M (in $), with an average decrease of 305.2% per quarter

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 89.8%

Institutional Holdings

  • Paradigm Biocapital Advisors LP

    8.68%

  • BlackRock Inc

    6.59%

  • Sofinnova Ventures

    4.92%

  • Vanguard Group Inc

    4.39%

  • Polar Capital Holdings PLC

    4.11%

  • Cormorant Asset Management, LLC

    3.25%

Company Information

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

Organization
Y-mabs Therapeutics Inc.
Employees
100
CEO
Mr. Michael Rossi
Industry
Health Technology

Discover More

FAQs